

OncoMethylome Sciences SA

Limited Liability Company (Société Anonyme)
 Tour 5 GIGA - Avenue de l'Hôpital 11 - B-4000 Liège, Belgium
 Register of Legal Persons (Liège) under Company Number 0479.292.440

Overview of History of Capital as per April 15, 2009

The table and notes below provide an overview of the history of OncoMethylome Sciences' share capital since its incorporation.

Date	Transaction	Number of shares issued	Issue price per share (€)	Issue price per share post stock-split (€)	Capital increase (€)	Share capital after transaction (€)	Share Issuance Premium after transaction (€)	Aggregate # of shares after capital increase
Incorporation								
Jan. 10, 2003	Incorporation (1)	202,975	0.30	0.06	61,500.00	61,500.00	0.00	202,975
Phase I Financing Round December 20, 2002 (Preferred A Shares)								
Feb. 7, 2003	Capital increase in cash (2)	197,025	20.00	4.00	3,940,500.00	4,002,000.00	0.00	400,000
Jun. 30, 2003	Capital increase in cash (3)	33,333	20.00	4.00	666,660.00	4,668,660.00	0.00	433,333
Sep. 30, 2003	Capital increase in cash (4)	218,139	22.31	4.46	4,866,681.09	9,535,341.09	0.00	651,472
Jun. 20, 2004	Capital increase in cash (5)	195,504	23.87	4.77	4,666,680.48	14,202,021.57	0.00	846,976
Phase II Financing Round October 19, 2005 (Preferred B Shares)								
Oct. 28, 2005	Capital increase in cash (6)	375,000	24,00 (7)	4,80 (7)	9,000,000.00	23,202,021.57	0.00	1,221,976
Mar. 31, 2006	Capital increase in cash (8)	193,548	31.00	6.20	5,999,988.00	29,202,009.57	0.00	1,415,524
May 23, 2006	Stock split 5/1	/	/	/	/	/	0.00	7,077,620
Initial Public Offering and Exercise of Over-Allotment Warrants								
Jun. 30, 2006	Capital increase in cash (9)	2,933,334	7.50	7.50	22,000,005.00	51,202,014.57	0.00	10,010,954
Jun. 30, 2006	Capital decrease (10)	/	/	/	-10,217,809.00	40,984,205.57	0.00	10,010,954
Jun. 30, 2006	Capital increase through exercise of warrants (11)	440,000	7.50	7.50	1,817,200.00	42,801,405.57	1,482,800.00	10,450,954
Exercise of Warrants								
Apr. 18, 2007	Capital increase through exercise of warrants (12)	182,560	4.70	4.70	747,666.16	43,549,071.73	1,593,731.31	10,633,514
Private Placement								
Oct. 19, 2007	Capital increase in cash (13)	1,063,351	10.00	10.00	4,354,954.02	47,904,025.75	7,872,287.29	11,696,865
Exercise of Warrants								
Oct. 25, 2007	Capital increase through exercise of warrants (14)	50,837	4.73	4.73	208,202.93	48,112,228.68	7,904,487.77	11,747,702
Exercise of Warrants								
Apr. 24, 2008	Capital increase through exercise of warrants (15)	61,120	4.59	4.59	250,316.96	48,362,545.64	7,934,871.81	11,808,822
Nov. 5, 2008	Capital increase through exercise of warrants (16)	19,375	4.73	4.73	79,350.31	48,441,895.95	7,947,140.25	11,828,197
Private Placement								
Dec. 18, 2008	Capital increase in cash (17)	1,332,877	6.29	6.29	5,458,797.75	53,900,693.70	10,872,138.83	13,161,074
Exercise of Warrants								
Apr. 15, 2009	Capital increase through exercise of warrants (18)	24,540	4.49	4.49	100,503.57	54,001,197.27	10,881,808.74	13,185,614
Current Situation								
Per statutory accounts						54,001,197.27	10,881,808.74	13,185,614
Per IFRS consolidated accounts (19)						51,089,274.00	10,881,808.74	13,185,614

Notes

- (1) *The shares were subscribed to by BBL NV/SA (ING Belgium NV/SA) (202,974 shares) and PolyTechnos Venture Fund II GmbH & Co KG (1 share). On January 30, 2003, 200,000 shares were transferred to the management and consultants of the Company. Of these 200,000 shares, 199,999 shares were transferred by BBL NV/SA (ING Belgium NV/SA) and 1 share was transferred by PolyTechnos Venture Fund II GmbH & Co KG.*
- (2) *The shares were subscribed to by BBL NV/SA (ING Belgium NV/SA) (97,025 shares), PolyTechnos Venture Fund II GmbH & Co KG (11,833 shares), PolyTechnos Venture Fund II LP (47,500 shares), PolyTechnos Venture Fund Beteiligungs GmbH (6,667 shares), PolyTechnos Partners & Team GmbH (667 shares), Technowal SA (16,667 shares), Société d'Investissement du Bassin Liégeois (SIBL) SA (8,333 shares and Société de Développement et de Participation du Bassin de Liège (Meusinvest) SA (8,333 shares). At the same occasion, two different classes of shares were created, i.e., the common shares and the preferred A shares. All shares issued at this occasion and 2,975 shares issued at incorporation were reclassified as preferred A shares. The remaining 200,000 shares are common shares.*
- (3) *The shares were all subscribed to by Life Sciences Partners II B.V.*
- (4) *The shares were subscribed to by ING Belgium NV/SA (89,646 shares), PolyTechnos Venture Fund II GmbH & Co KG (4,997 shares), PolyTechnos Venture Fund II LP (20,062 shares), PolyTechnos Venture Fund Beteiligungs GmbH (2,816 shares), PolyTechnos Partners & Team GmbH (281 shares), Technowal SA (14,940 shares), SIBL SA (7,471 shares), Meusinvest SA (7,471 shares), Life Sciences Partners II B.V. (61,490 shares) and Mr. Pierre Hochuli (8,965 shares).*
- (5) *The shares were subscribed to by ING Belgium NV/SA (83,787 shares), PolyTechnos Venture Fund II GmbH & Co KG (7,435 shares), PolyTechnos Venture Fund II LP (29,850 shares), PolyTechnos Venture Fund Beteiligungs GmbH (4,190 shares), PolyTechnos Partners & Team GmbH (419 shares), Technowal SA (13,965 shares), SIBL SA (6,982 shares), Meusinvest SA (6,982 shares) and Life Sciences Partners II B.V. (41,894 shares).*
- (6) *The shares were subscribed to by ING Belgium NV/SA (105,658 shares), PolyTechnos Venture Fund II GmbH & Co KG (9,376 shares), PolyTechnos Venture Fund II LP (37,641 shares), PolyTechnos Venture Fund Beteiligungs GmbH (5,284 shares), PolyTechnos Partners & Team GmbH (528 shares), Technowal SA (19,484 shares), Meusinvest SA (9,742 shares), Life Sciences Partners II B.V. (58,453 shares), Mr. Pierre Hochuli (3,834 shares), BioDiscovery II FCPR (100,000 shares), Innovation Discovery 3 FCPI (10,500 shares), Sogé Innovation Evolution 2 FCPI (9,750 shares) and Sogé Innovation Evolution 4 FCPI (4,750 shares).*
- (7) *The issue price was €24 (or €4.80 after stock split), being €16.77 (or €3.35 after stock split), being the fractional value of the shares, increased with €7.23 (or €1.45 after stock split), being the issue premium, per share. The total amount of the issue premium was immediately incorporated in the share capital of the Company.*
- (8) *This capital increase was executed pursuant to and in accordance with the terms and conditions of an agreement entered into on October 19, 2005 with respect to the Phase II financing round. The shares were subscribed to by ING Belgium NV/SA (54,533 shares), PolyTechnos Venture Fund II GmbH & Co KG (2,420 shares), PolyTechnos Venture Fund II LP (9,714 shares), PolyTechnos Venture Fund Beteiligungs GmbH (14,996 shares), PolyTechnos Partners & Team GmbH (137 shares), Technowal SA (10,056 shares), Meusinvest SA (5,028 shares), Life Sciences Partners II B.V. (30,169 shares), Mr. Pierre Hochuli (1,979 shares), BioDiscovery II FCPR (51,613 shares), Innovation Discovery 3 FCPI (5,419 shares), Sogé Innovation Evolution 2 FCPI (5,032 shares) and Sogé Innovation Evolution 4 FCPI (2,452 shares).*
- (9) *On May 23, 2006, the general shareholders' meeting of the Company decided to increase the Company's share capital with the issuance of new shares in connection with an initial public offering. The capital increase was completed on June 30, 2006. At the same time, all existing shares of the Company were converted into ordinary shares.*
- (10) *On May 23, 2006, the general shareholders' meeting of the Company decided to decrease the Company's share capital with an amount of €10,217,809 through incorporation of losses. The capital decrease was completed on June 30, 2006.*
- (11) *On May 23, 2006, the general shareholders' meeting of the Company decided to create an over-allotment warrant. The over-allotment warrant was granted to ING Belgium NV/SA and Fortis Bank NV/SA to cover over-allotments in connection with the initial public offering by the Company. On June 30, 2006, the share capital was increased through exercise of 440,000 over-allotment warrants and the issuance of 440,000 new ordinary shares.*
- (12) *On April 18, 2007, 182,560 new shares were issued for an aggregate issue price of €858,597.47 with respect to the exercise of warrants in March 2007. The exercised warrants were vested warrants related to the Warrant Plans of 2004, 2005, and March 2006 which had been granted to employees, directors, and consultants.*
- (13) *On October 19, 2007, 1,063,351 new shares were issued for an aggregate issue price of €10,633,510.00 with respect to a private placement of new shares with institutional and qualified investors.*
- (14) *On October 25, 2007, 50,837 new shares were issued for an aggregate issue price of €240,403.19 with respect to the exercise of warrants in September 2007. The exercised warrants were vested warrants related to the Warrant Plans of 2004, 2005, March 2006, November 2007, and April 2007 which had been granted to employees, directors, and consultants.*
- (15) *On April 24, 2008, 61,120 new shares were issued for an aggregate issue price of €280,701.00 with respect to the exercise of warrants in March 2008. The exercised warrants were vested warrants related to the Warrant Plans of 2004 and March 2006 which had been granted to employees and consultants.*
- (16) *On November 5, 2008, 19,375 new shares were issued for an aggregate issue price of €91,618.75 with respect to the exercise of warrants in September 2008. The exercised warrants were vested warrants related to the Warrant Plans of 2004, 2005, and March 2006 which had been granted to employees, directors and consultants.*
- (17) *On December 18, 2008, 1332,877 new shares were issued for an aggregate issue price of €8,383,796.33 with respect to a private placement of new shares with institutional and qualified investors.*
- (18) *On April 15, 2009, 24,540 new shares were issued for an aggregate issue price of €110,173.48 with respect to the exercise of warrants in March 2009. The exercised warrants were vested warrants related to the Warrant Plans of 2004 and March 2006 which had been granted to employees and consultants.*
- (19) *For the consolidated IFRS accounts, the IPO expenses of June 30, 2006 and the expenses of the private placement of October 2007 and December 2008 were recorded as a reduction in the share capital, whereas they were recorded as an expense for the statutory accounts.*